Previous 10 | Next 10 |
In fast-changing industries, it’s not always easy to know which companies offer the most promising investment opportunities. The electrification of the automotive industry is a megatrend that many investors want to capture, given its expected industry growth. For investors,...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2021 financial results before the market opens on Tuesday, July 27, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings r...
Stanley Druckenmiller’s 13F portfolio value increased from $3.71B to $3.89B this quarter. Duquesne added Citigroup and Palantir Technologies while dropping Walt Disney. The top three positions are at 25% of the portfolio. For further details see: Tracking Stanley ...
Myriad Genetics ([[MYGN]] +2.4%) has completed the sale of its laboratory subsidiary, Myriad RBM, to Q2 Solutions, a global clinical trial laboratory services organization owned by IQVIA ([[IQV]] +2.0%). The divesture was announced in May. For further details see: Myriad Genet...
metamorworks/iStock via Getty Images M&A activity tends to cycle with overall market direction and level of margin debt. And deals could be poised to eclipse their 2015 highs, BTIG Chief Equity and Derivatives Strategist Julian Emanuel writes in a recent note. "Many companies whose shares...
IQVIA™ (NYSE: IQV) today introduced Clinical Data Analytics Suite (CDAS) , a new SaaS-based clinical data analytics platform that combines structured and unstructured data from clinical trials into a single, standardized setting for easier access and use. This produces a scal...
Q 2 Solutions, a leading global clinical trial laboratory services organization and a wholly owned subsidiary of IQVIA, has announced the expansion of its laboratory and operational capabilities at its Alba Campus in Livingston, Scotland. This expansion of central labs, genomics, fl...
Glenview Capital Management’s 13F portfolio value increased from $4.36B to $5.90B this quarter. The number of positions increased from 54 to 63. They increased AmerisourceBergen, Facebook, Alphabet, and Baxter International while reducing Laboratory Corp. and dropping Expedia G...
Q 2 Solutions, a wholly-owned subsidiary of IQVIA and a leading clinical trial laboratory services organization, today announced a transformative collaboration with Tasso Inc., a pioneer in clinical-grade, at-home, patient-centered blood testing, to develop diagnostic tests used in ...
Dan Loeb's 13F portfolio value increased from ~$13B to $14.83B this quarter. The number of positions increased from 73 to 125. Third Point added Paysafe, CoStar Group, and Uber Technologies while dropping Alibaba Group Holdings and Fidelity National Information Services. The top t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...